middl
east
respiratori
syndrom
coronaviru
merscov
ongo
emerg
infecti
diseas
across
arabian
peninsula
major
case
occur
saudi
arabia
septemb
world
health
organ
report
total
case
includ
death
countri
http
wwwwho
intemergenciesmerscoven
diseas
compris
lower
respiratori
infect
wherein
individu
exhibit
pneumonialik
symptom
often
lead
multiorgan
failur
death
addit
close
contact
infect
camel
transmiss
humantohuman
commonli
occur
hospit
set
close
contact
patient
hospit
worker
merscov
also
isol
object
within
patient
room
includ
bed
sheet
bed
rail
iv
fluid
hanger
may
potenti
sourc
transmiss
sever
case
merscov
associ
travel
return
home
middl
east
develop
symptom
includ
two
case
health
care
worker
return
unit
state
potenti
global
spread
recent
illustr
south
korean
nation
return
home
visit
arabian
peninsula
may
initi
outbreak
infect
peopl
result
mortal
nationwid
econom
crisi
nonetheless
merscov
thought
sustain
human
popul
humantohuman
transmiss
may
instead
continu
reintroduc
human
popul
zoonot
sourc
like
dromedari
camel
high
seroposit
rate
herd
throughout
middl
east
camel
integr
saudi
arabian
cultur
economi
nationwid
cull
camel
herd
feasibl
consequ
camel
vaccin
consid
howev
therapeut
strategi
primarili
focus
interf
merscov
infect
human
date
therapeut
strategi
limit
combin
ribavirin
interferon
therapi
littl
evid
efficaci
predomin
form
support
continu
palli
care
includ
oxygen
deliveri
standard
ventil
extracorpor
membran
oxygen
ecmo
sever
case
progress
acut
respiratori
distress
syndrom
ard
number
human
neutral
antibodi
direct
merscov
develop
phase
clinic
trial
recent
initi
use
transchromosom
bovin
product
system
produc
human
polyclon
merscov
antibodi
consid
diagnos
case
merscov
typic
present
hospit
day
initi
infect
merscovdirect
therapi
neutral
antibodi
may
outsid
therapeut
window
effect
quell
develop
immun
patholog
ard
diseas
phenotyp
hospit
diagnos
case
earli
detect
contacttrac
infect
hostdirect
therapeut
intervent
may
benefici
nonetheless
neutral
antibodi
therapi
could
provid
highli
effect
prophylact
treatment
hospit
staff
work
close
infect
individu
therapeut
intervent
effect
strategi
immedi
respons
newli
diagnos
case
hospit
set
widespread
prophylact
treatment
practic
effect
prophylact
treatment
would
develop
efficaci
vaccin
merscov
vaccin
elicit
proper
adapt
immun
respons
provid
longterm
protect
may
benefici
popul
across
arabian
peninsula
especi
consid
persist
threat
reintroduct
merscov
dromedari
camel
decad
work
coronaviru
vaccin
demonstr
spike
protein
major
determin
viral
tropism
elicit
strong
neutral
antibodi
respons
effect
protect
model
organ
challeng
homolog
sarscov
protect
cell
respons
target
nucleocapsid
protein
also
proven
effect
prevent
death
clinic
diseas
sarscov
infect
rodent
build
upon
knowledg
sarscov
vaccin
muthumani
et
al
develop
novel
dna
vaccin
design
elicit
adapt
immun
respons
merscov
spike
protein
enhanc
success
dna
vaccin
muthumani
et
al
built
consensu
spike
protein
deriv
merscov
spike
genom
sequenc
repres
clade
b
vaccin
efficaci
evalu
three
differ
mammalian
speci
use
dose
deliveri
regimen
prime
two
boost
mice
week
interv
three
dromedari
camel
week
interv
rhesu
macaqu
week
interv
import
gaug
vaccin
efficaci
cellular
humor
adapt
immun
respons
elicit
specif
merscov
spike
protein
muthumani
et
al
identifi
set
immunodomin
merscovspecif
spike
epitop
convincingli
activ
cell
isol
vaccin
mice
nonhuman
primat
nhp
cellular
immun
respons
evalu
vaccin
camel
humor
immun
respons
evalu
mice
camel
nhp
effect
measur
humor
immun
respons
viral
antigen
capac
vaccin
elicit
antibodi
neutral
viral
infect
cellular
assay
dnaspik
vaccin
mice
nhp
gener
antibodi
capabl
neutral
strain
merscov
vaccin
appear
less
effect
camel
exhibit
vari
degre
neutral
activ
lack
neutral
activ
vaccin
camel
muthumani
et
al
extend
humor
respons
observ
merscov
determin
serum
could
neutral
heterotyp
spike
protein
human
coronavirus
commonli
associ
mildupp
respiratori
tract
infect
serum
mice
nhp
could
effect
neutral
spike
protein
neutral
assay
design
around
pseudotyp
lentivir
vector
particl
howev
recogn
muthumani
et
al
assay
may
reflect
activ
antibodi
may
exhibit
spike
protein
present
nativ
coronaviru
context
other
shown
cross
neutral
coronaviru
genu
speci
lack
live
viru
use
overal
muthumani
et
al
convincingli
demonstr
consensu
merscov
dna
spike
vaccin
elicit
effect
adapt
immun
respons
mice
nhp
lesser
extent
camel
gener
adapt
immun
across
multipl
mammalian
speci
provid
strong
preclin
support
translat
merscov
dna
spike
vaccin
platform
human
applic
also
offer
hope
vaccin
soon
emin
prevent
merscov
infect
human
reservoir
anim
speci
howev
true
baromet
vaccin
efficaci
well
vaccin
anim
model
protect
develop
diseas
symptom
follow
challeng
infecti
dose
merscov
turn
complic
avail
anim
model
accur
reflect
merscov
patholog
human
accordingli
proper
model
develop
requir
understand
merscov
patholog
human
clear
pictur
merscov
pathogenesi
human
hamper
cultur
constraint
prevent
autopsi
procur
human
sampl
fatal
case
saudi
arabia
januari
singl
public
describ
histopatholog
immunohistochem
ultrastructur
find
singl
fatal
case
merscov
unit
arab
emir
merscov
antigen
detect
lung
histopatholog
consist
diffus
alveolar
damag
associ
ard
detect
merscov
antigen
extrapulmonari
tissu
therefor
efficaci
vaccin
platform
could
minim
anticip
protect
model
organ
patholog
consist
merscovinduc
ard
recent
new
mous
model
describ
reproduc
sever
end
stage
lung
diseas
phenotyp
like
ard
provid
new
mous
model
prophylat
therapeut
test
well
muthumani
inovio
util
proprietari
platform
initi
phase
clinic
dna
vaccin
studi
merscov
zika
viru
ebola
viru
http
wwwinoviocom
dna
vaccin
provid
number
advantag
vaccin
approach
recombin
protein
liveattenu
vaccin
develop
cost
effect
easier
ii
risk
revers
iii
membran
protein
target
eg
viral
membran
glycoprotein
readili
express
mammalian
cell
iv
prior
phase
clinic
studi
indic
littl
inflamm
toxic
associ
dna
vaccin
despit
advantag
approv
dna
vaccin
use
human
dna
vaccin
elicit
effect
immun
respons
infecti
diseas
antigen
continu
challeng
human
describ
number
former
clinic
trial
tregon
et
al
describ
impedi
dna
vaccin
field
may
contribut
lack
success
previou
clinic
trial
includ
inabl
adequ
scaleup
product
ii
differ
innat
immun
respons
mammalian
model
human
requir
initi
appropri
adapt
immun
respons
iii
optim
method
deliveri
recogn
one
biggest
challeng
field
iv
effect
protein
express
preclin
studi
muthumani
et
al
success
address
impedi
demonstr
capac
elicit
effect
adapt
immun
respons
small
mammal
mice
medium
size
mammal
rhesu
macaqu
larg
mammal
dromedari
camel
address
impedi
three
inovio
develop
proprietari
electropor
technolog
achiev
effici
deliveri
vaccin
plasmid
dna
nucleu
cell
express
viral
immunogen
occur
numer
dna
vaccin
trial
underway
let
us
hope
efficaci
vaccin
platform
human
reveal
within
next
year
dna
vaccin
platform
effici
mean
rapidli
respond
emerg
infecti
diseas
eg
vaccin
clinic
trial
zika
viru
merscov
ebola
viru
conclud
remark
would
like
address
concern
may
influenc
longterm
efficaci
safeti
profil
dna
vaccin
earli
preclin
studi
anim
model
rais
potenti
safeti
concern
later
adopt
fda
guidanc
industri
address
immunogen
safeti
dna
deliveri
platform
safeti
concern
rais
includ
garner
understand
biodistribut
persist
integr
profil
potenti
associ
deliveri
dna
molecul
nucleu
mammalian
cell
ii
potenti
autoimmun
iii
transfer
antibiot
resist
gene
patient
tregon
et
al
indic
due
accumul
success
multipl
phase
clinic
studi
last
decad
fda
guidelin
becom
relax
time
caveat
fda
guidelin
includ
waiver
biodistribut
studi
novel
gene
insert
plasmid
vector
previous
document
accept
biodistributionintegr
profil
integr
studi
warrant
plasmid
persist
tissu
anim
level
exceed
copi
per
host
dna
studi
termin
curious
preclin
research
studi
establish
preced
assess
biodistributionintegr
profil
perform
decad
ago
prior
initi
human
clinic
trial
continu
referenc
establish
preced
lack
detect
biodistributionintegr
look
toward
futur
light
numer
dna
vaccin
trial
progress
might
prudent
reevalu
question
use
highli
sensit
modern
molecular
biolog
technolog
commonli
employ
gene
therapi
field
profil
human
genom
put
site
insert
mutagenesi
